Dysregulation of histone methyltransferases in breast cancer – Opportunities for new targeted therapies?

Molecular Oncology

Volumn 10, Issue 10, 2016, Pages 1497-

  Michalak, Ewa M ^a,b   Visvader, Jane E ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast cancer; Chromatin; Histone methyltransferase; Inhibitors; Transcription

Indexed keywords

ARGININE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; DOT1 LIKE LYSINE METHYLTRANSFERASE; H3K27 METHYLTRANSFERASE; H3K36 METHYLTRANSFERASE; H3K4 METHYLTRANSFERASE; H3K79 METHYLTRANSFERASE; H3K9 METHYLTRANSFERASE; H4K20 METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE; PRMT PROTEIN; PROTEIN; SMYD PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE;

BREAST CANCER; CANCER THERAPY; DRUG TARGETING; GENE TARGETING; HISTONE METHYLATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; DRUG DEVELOPMENT; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HISTONE CODE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; DRUG DISCOVERY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE CODE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN-ARGININE N-METHYLTRANSFERASES; TRANSCRIPTIONAL ACTIVATION;

EID: 85002202351     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.09.003     Document Type: Review

References (199)

1. Abbondanza, C., De Rosa, C., D'Arcangelo, A., Pacifico, M., Spizuoco, C., Piluso, G., Di Zazzo, E., Gazzerro, P., Medici, N., Moncharmont, B., Puca, G.A., Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines. J. Cell. Physiol. 227 (2012), 964–975, 10.1002/jcp.22803.
2. Al-Dhaheri, M., Wu, J., Skliris, G.P., Li, J., Higashimato, K., Wang, Y., White, K.P., Lambert, P., Zhu, Y., Murphy, L., Xu, W., CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res. 71 (2011), 2118–2128, 10.1158/0008-5472.CAN-10-2426.
3. Ancelin, K., Lange, U.C., Hajkova, P., Schneider, R., Bannister, A.J., Kouzarides, T., Surani, M.A., Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat. Cell Biol. 8 (2006), 623–630, 10.1038/ncb1413.
4. Asangani, I.A., Ateeq, B., Cao, Q., Dodson, L., Pandhi, M., Kunju, L.P., Mehra, R., Lonigro, R.J., Siddiqui, J., Palanisamy, N., Wu, Y.-M., Cao, X., Kim, J.H., Zhao, M., Qin, Z.S., Iyer, M.K., Maher, C.A., Kumar-Sinha, C., Varambally, S., Chinnaiyan, A.M., Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol. Cell 49 (2013), 80–93, 10.1016/j.molcel.2012.10.008.
5. Audia, J.E., Campbell, R.M., Histone modifications and cancer. Cold Spring Harb. Perspect. Biol., 8, 2016, 10.1101/cshperspect.a019521.
6. Bachmann, I.M., Halvorsen, O.J., Collett, K., Stefansson, I.M., Straume, O., Haukaas, S.A., Salvesen, H.B., Otte, A.P., Akslen, L.A., EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24 (2006), 268–273, 10.1200/JCO.2005.01.5180.
7. Bae, W.K., Hennighausen, L., Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer. Mol. Cell. Endocrinol. 382 (2014), 593–597, 10.1016/j.mce.2013.05.002.
8. Bae, W.K., Yoo, K.H., Lee, J.S., Kim, Y., Chung, I.-J., Park, M.H., Yoon, J.H., Furth, P.A., Hennighausen, L., The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol. Carcinog. 54 (2014), 1172–1180, 10.1002/mc.22188.
9. Baldwin, R.M., Haghandish, N., Daneshmand, M., Amin, S., Paris, G., Falls, T.J., Bell, J.C., Islam, S., Côté, J., Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget 6 (2015), 3013–3032, 10.18632/oncotarget.3072.
10. Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, I., Zhao, K., High-resolution profiling of histone methylations in the human genome. Cell 129 (2007), 823–837, 10.1016/j.cell.2007.05.009.
11. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, I.-M., Conejo-Garcia, J.R., Speicher, D.W., Zhang, R., Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21 (2015), 231–238, 10.1038/nm.3799.
12. Borley, J., Brown, R., Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann. Med. 47 (2015), 359–369, 10.3109/07853890.2015.1043140.
13. Bradley, W.D., Arora, S., Busby, J., Balasubramanian, S., Gehling, V.S., Nasveschuk, C.G., Vaswani, R.G., Yuan, C.-C., Hatton, C., Zhao, F., Williamson, K.E., Iyer, P., Méndez, J., Campbell, R., Cantone, N., Garapaty-Rao, S., Audia, J.E., Cook, A.S., Dakin, L.A., Albrecht, B.K., Harmange, J.-C., Daniels, D.L., Cummings, R.T., Bryant, B.M., Normant, E., Trojer, P., EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem. Biol. 21 (2014), 1463–1475, 10.1016/j.chembiol.2014.09.017.
14. Brien, G.L., Valerio, D.G., Armstrong, S.A., Exploiting the epigenome to control cancer-promoting gene-expression programs. Cancer Cell 29 (2016), 464–476, 10.1016/j.ccell.2016.03.007.
15. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70, 10.1038/nature11412.
16. Cao, F., Townsend, E.C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., Hess, J.L., Atadja, P., Lei, M., Qin, Z.S., Malek, S., Wang, S., Dou, Y., Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53 (2014), 247–261, 10.1016/j.molcel.2013.12.001.
17. Carofino, B.L., Ayanga, B., Justice, M.J., A mouse model for inducible overexpression of Prdm14 results in rapid-onset and highly penetrant T-cell acute lymphoblastic leukemia (T-ALL). Dis. Model Mech. 6 (2013), 1494–1506, 10.1242/dmm.012575.
18. Casciello, F., Windloch, K., Gannon, F., Lee, J.S., Functional role of G9a histone methyltransferase in cancer. Front Immunol., 6, 2015, 487, 10.3389/fimmu.2015.00487.
19. Chan-Penebre, E., Kuplast, K.G., Majer, C.R., Boriack-Sjodin, P.A., Wigle, T.J., Johnston, L.D., Rioux, N., Munchhof, M.J., Jin, L., Jacques, S.L., West, K.A., Lingaraj, T., Stickland, K., Ribich, S.A., Raimondi, A., Scott, M.P., Waters, N.J., Pollock, R.M., Smith, J.J., Barbash, O., Pappalardi, M., Ho, T.F., Nurse, K., Oza, K.P., Gallagher, K.T., Kruger, R., Moyer, M.P., Copeland, R.A., Chesworth, R., Duncan, K.W., A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat. Chem. Biol. 11 (2015), 432–437, 10.1038/nchembio.1810.
20. Chang, Y., Sun, L., Kokura, K., Horton, J.R., Fukuda, M., Espejo, A., Izumi, V., Koomen, J.M., Bedford, M.T., Zhang, X., Shinkai, Y., Fang, J., Cheng, X., MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP/G9a. Nat. Commun., 2, 2011, 533, 10.1038/ncomms1549.
21. Chapman-Rothe, N., Curry, E., Zeller, C., Liber, D., Stronach, E., Gabra, H., Ghaem-Maghami, S., Brown, R., Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene 32 (2013), 4586–4592, 10.1038/onc.2012.477.
22. Chen, J., Luo, Q., Yuan, Y., Huang, X., Cai, W., Li, C., Wei, T., Zhang, L., Yang, M., Liu, Q., Ye, G., Dai, X., Li, B., Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. Mol. Cell. Biol. 30 (2010), 5621–5635, 10.1128/MCB.00465-10.
23. Chen, Y., McGee, J., Chen, X., Doman, T.N., Gong, X., Zhang, Y., Hamm, N., Ma, X., Higgs, R.E., Bhagwat, S.V., Buchanan, S., Peng, S.-B., Staschke, K.A., Yadav, V., Yue, Y., Kouros-Mehr, H., Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One, 9, 2014, e98293, 10.1371/journal.pone.0098293.
24. Cho, M.-H., Park, J.-H., Choi, H.-J., Park, M.-K., Won, H.-Y., Park, Y.-J., Lee, C.H., Oh, S.-H., Song, Y.-S., Kim, H.S., Oh, Y.-H., Lee, J.-Y., Kong, G., DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat. Commun., 6, 2015, 7821, 10.1038/ncomms8821.
25. Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., Bowlby, R., Shen, H., Hayat, S., Fieldhouse, R., Lester, S.C., Tse, G.M.K., Factor, R.E., Collins, L.C., Allison, K.H., Chen, Y.-Y., Jensen, K., Johnson, N.B., Oesterreich, S., Mills, G.B., Cherniack, A.D., Robertson, G., Benz, C., Sander, C., Laird, P.W., Hoadley, K.A., King, T.A. TCGA Research Network, Perou, C.M., Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163 (2015), 506–519, 10.1016/j.cell.2015.09.033.
26. Collett, K., Eide, G.E., Arnes, J., Stefansson, I.M., Eide, J., Braaten, A., Aas, T., Otte, A.P., Akslen, L.A., Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 12 (2006), 1168–1174, 10.1158/1078-0432.CCR-05-1533.
27. Crea, F., Fornaro, L., Paolicchi, E., Masi, G., Frumento, P., Loupakis, F., Salvatore, L., Cremolini, C., Schirripa, M., Graziano, F., Ronzoni, M., Ricci, V., Farrar, W.L., Falcone, A., Danesi, R., An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol. 23 (2012), 1207–1213, 10.1093/annonc/mdr387.
28. Curtis, C., Shah, S.P., Chin, S.-F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S. METABRIC Group, Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Børresen-Dale, A.-L., Brenton, J.D., Tavaré, S., Caldas, C., Aparicio, S., The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486 (2012), 346–352, 10.1038/nature10983.
29. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P., Waters, N.J., Chesworth, R., Moyer, M.P., Copeland, R.A., Richon, V.M., Pollock, R.M., Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122 (2013), 1017–1025, 10.1182/blood-2013-04-497644.
30. de Vries, N.A., Hulsman, D., Akhtar, W., de Jong, J., Miles, D.C., Blom, M., van Tellingen, O., Jonkers, J., van Lohuizen, M., Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Rep. 10 (2015), 383–397, 10.1016/j.celrep.2014.12.028.
31. Deng, Q., Huang, S., PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 23 (2004), 4903–4910, 10.1038/sj.onc.1207615.
32. Ding, L., Kleer, C.G., Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res. 66 (2006), 9352–9355, 10.1158/0008-5472.CAN-06-2384.
33. Dong, C., Wu, Y., Yao, J., Wang, Y., Yu, Y., Rychahou, P.G., Evers, B.M., Zhou, B.P., G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J. Clin. Invest. 122 (2012), 1469–1486, 10.1172/JCI57349.
34. Dowhan, D.H., Harrison, M.J., Eriksson, N.A., Bailey, P., Pearen, M.A., Fuller, P.J., Funder, J.W., Simpson, E.R., Leedman, P.J., Tilley, W.D., Brown, M.A., Clarke, C.L., Muscat, G.E.O., Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr. Relat. Cancer 19 (2012), 509–526, 10.1530/ERC-12-0100.
35. Du, J., Johnson, L.M., Jacobsen, S.E., Patel, D.J., DNA methylation pathways and their crosstalk with histone methylation. Nat. Rev. Mol. Cell Biol. 16 (2015), 519–532, 10.1038/nrm4043.
36. Du, Y., Carling, T., Fang, W., Piao, Z., Sheu, J.C., Huang, S., Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 61 (2001), 8094–8099.
37. Edmunds, J.W., Mahadevan, L.C., Clayton, A.L., Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 27 (2008), 406–420, 10.1038/sj.emboj.7601967.
38. Ezhkova, E., Lien, W.-H., Stokes, N., Pasolli, H.A., Silva, J.M., Fuchs, E., EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 25 (2011), 485–498, 10.1101/gad.2019811.
39. Falahi, F., Huisman, C., Kazemier, H.G., van der Vlies, P., Kok, K., Hospers, G.A.P., Rots, M.G., Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol. Cancer Res. 11 (2013), 1029–1039, 10.1158/1541-7786.MCR-12-0567.
40. Falandry, C., Fourel, G., Galy, V., Ristriani, T., Horard, B., Bensimon, E., Salles, G., Gilson, E., Magdinier, F., CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation. J. Biol. Chem. 285 (2010), 20234–20241, 10.1074/jbc.M109.052399.
41. Faria, J.A.Q.A., Corrêa, N.C.R., de Andrade, C., de Angelis Campos, A.C., Santos Samuel de Almeida, Dos, R., Rodrigues, T.S., de Goes, A.M., Gomes, D.A., Silva, F.P., Set domain-containing protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation. J. Cancer Sci. Ther. 5 (2013), 58–65.
42. Fraga, M.F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N.G., Pérez-Rosado, A., Calvo, E., Lopez, J.A., Cano, A., Calasanz, M.J., Colomer, D., Piris, M.A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., Esteller, M., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37 (2005), 391–400, 10.1038/ng1531.
43. Gao, Y., Zhao, Y., Zhang, J., Lu, Y., Liu, X., Geng, P., Huang, B., Zhang, Y., Lu, J., The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1. Sci. Rep., 6, 2016, 19874, 10.1038/srep19874.
44. Gazzerro, P., Abbondanza, C., D'Arcangelo, A., Rossi, M., Medici, N., Moncharmont, B., Puca, G.A., Modulation of RIZ gene expression is associated to estradiol control of MCF-7 breast cancer cell proliferation. Exp. Cell Res. 312 (2006), 340–349, 10.1016/j.yexcr.2005.11.002.
45. Gonzalez, M.E., Li, X., Toy, K., DuPrie, M., Ventura, A.C., Banerjee, M., Ljungman, M., Merajver, S.D., Kleer, C.G., Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28 (2009), 843–853, 10.1038/onc.2008.433.
46. Gonzalez, M.E., Moore, H.M., Li, X., Toy, K.A., Huang, W., Sabel, M.S., Kidwell, K.M., Kleer, C.G., EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl. Acad. Sci. U.S.A 111 (2014), 3098–3103, 10.1073/pnas.1308953111.
47. Goulet, I., Gauvin, G., Boisvenue, S., Côté, J., Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J. Biol. Chem. 282 (2007), 33009–33021, 10.1074/jbc.M704349200.
48. Greer, E.L., Shi, Y., Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13 (2012), 343–357, 10.1038/nrg3173.
49. Guccione, E., Bassi, C., Casadio, F., Martinato, F., Cesaroni, M., Schuchlautz, H., Lüscher, B., Amati, B., Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 449 (2007), 933–937, 10.1038/nature06166.
50. Gyory, I., Wu, J., Fejér, G., Seto, E., Wright, K.L., PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat. Immunol. 5 (2004), 299–308, 10.1038/ni1046.
51. Habashy, H.O., Rakha, E.A., Ellis, I.O., Powe, D.G., The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. Breast Cancer Res. Treat. 140 (2013), 307–316, 10.1007/s10549-013-2614-y.
52. Hamamoto, R., Silva, F.P., Tsuge, M., Nishidate, T., Katagiri, T., Nakamura, Y., Furukawa, Y., Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97 (2006), 113–118, 10.1111/j.1349-7006.2006.00146.x.
53. He, L., Yu, J.X., Liu, L., Buyse, I.M., Wang, M.S., Yang, Q.C., Nakagawara, A., Brodeur, G.M., Shi, Y.E., Huang, S., RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 58 (1998), 4238–4244.
54. Heintzman, N.D., Stuart, R.K., Hon, G., Fu, Y., Ching, C.W., Hawkins, R.D., Barrera, L.O., Van Calcar, S., Qu, C., Ching, K.A., Wang, W., Weng, Z., Green, R.D., Crawford, G.E., Ren, B., Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39 (2007), 311–318, 10.1038/ng1966.
55. Hidalgo, I., Herrera-Merchan, A., Ligos, J.M., Carramolino, L., Nuñez, J., Martinez, F., Dominguez, O., Torres, M., Gonzalez, S., Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell 11 (2012), 649–662, 10.1016/j.stem.2012.08.001.
56. Holm, K., Grabau, D., Lövgren, K., Aradottir, S., Gruvberger-Saal, S., Howlin, J., Saal, L.H., Ethier, S.P., Bendahl, P.-O., Stål, O., Malmström, P., Fernö, M., Rydén, L., Hegardt, C., Borg, Å., Ringnér, M., Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol. Oncol. 6 (2012), 494–506, 10.1016/j.molonc.2012.06.002.
57. Hsu, J.-M., Chen, C.-T., Chou, C.-K., Kuo, H.-P., Li, L.-Y., Lin, C.-Y., Lee, H.-J., Wang, Y.-N., Liu, M., Liao, H.-W., Shi, B., Lai, C.-C., Bedford, M.T., Tsai, C.-H., Hung, M.-C., Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat. Cell Biol. 13 (2011), 174–181, 10.1038/ncb2158.
58. Hu, D., Gur, M., Zhou, Z., Gamper, A., Hung, M.-C., Fujita, N., Lan, L., Bahar, I., Wan, Y., Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. Nat. Commun., 6, 2015, 8419, 10.1038/ncomms9419.
59. Hu, L., Zhu, Y.T., Qi, C., Zhu, Y.-J., Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 69 (2009), 4067–4072, 10.1158/0008-5472.CAN-08-4097.
60. Hua, K.-T., Wang, M.-Y., Chen, M.-W., Wei, L.-H., Chen, C.-K., Ko, C.-H., Jeng, Y.-M., Sung, P.-L., Jan, Y.-H., Hsiao, M., Kuo, M.-L., Yen, M.-L., The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol. Cancer, 13, 2014, 189, 10.1186/1476-4598-13-189.
61. Huang, J., Dorsey, J., Chuikov, S., Pérez-Burgos, L., Zhang, X., Jenuwein, T., Reinberg, D., Berger, S.L., G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 285 (2010), 9636–9641, 10.1074/jbc.M109.062588.
62. Huang, J., Pérez-Burgos, L., Placek, B.J., Sengupta, R., Richter, M., Dorsey, J.A., Kubicek, S., Opravil, S., Jenuwein, T., Berger, S.L., Repression of p53 activity by Smyd2-mediated methylation. Nature 444 (2006), 629–632, 10.1038/nature05287.
63. Jansson, M., Durant, S.T., Cho, E.-C., Sheahan, S., Edelmann, M., Kessler, B., La Thangue, N.B., Arginine methylation regulates the p53 response. Nat. Cell Biol. 10 (2008), 1431–1439, 10.1038/ncb1802.
64. Jene-Sanz, A., Váraljai, R., Vilkova, A.V., Khramtsova, G.F., Khramtsov, A.I., Olopade, O.I., Lopez-Bigas, N., Benevolenskaya, E.V., Expression of polycomb targets predicts breast cancer prognosis. Mol. Cell. Biol. 33 (2013), 3951–3961, 10.1128/MCB.00426-13.
65. Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G.A., Kadam, S., Zhai, H., Valdez, R., Gonzalo, S., Zhang, Y., Li, E., Chen, T., The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet., 4, 2008, e1000190, 10.1371/journal.pgen.1000190.
66. Jørgensen, S., Schotta, G., Sørensen, C.S., Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res. 41 (2013), 2797–2806, 10.1093/nar/gkt012.
67. Kamangar, F., Dores, G.M., Anderson, W.F., Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24 (2006), 2137–2150, 10.1200/JCO.2005.05.2308.
68. Kanchi, K.L., Johnson, K.J., Lu, C., McLellan, M.D., Leiserson, M.D.M., Wendl, M.C., Zhang, Q., Koboldt, D.C., Xie, M., Kandoth, C., McMichael, J.F., Wyczalkowski, M.A., Larson, D.E., Schmidt, H.K., Miller, C.A., Fulton, R.S., Spellman, P.T., Mardis, E.R., Druley, T.E., Graubert, T.A., Goodfellow, P.J., Raphael, B.J., Wilson, R.K., Ding, L., Integrated analysis of germline and somatic variants in ovarian cancer. Nat. Commun., 5, 2014, 3156, 10.1038/ncomms4156.
69. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., Leiserson, M.D.M., Miller, C.A., Welch, J.S., Walter, M.J., Wendl, M.C., Ley, T.J., Wilson, R.K., Raphael, B.J., Ding, L., Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339, 10.1038/nature12634.
70. Kaniskan, H.Ü., Szewczyk, M.M., Yu, Z., Eram, M.S., Yang, X., Schmidt, K., Luo, X., Dai, M., He, F., Zang, I., Lin, Y., Kennedy, S., Li, F., Dobrovetsky, E., Dong, A., Smil, D., Min, S.-J., Landon, M., Lin-Jones, J., Huang, X.-P., Roth, B.L., Schapira, M., Atadja, P., Barsyte-Lovejoy, D., Arrowsmith, C.H., Brown, P.J., Zhao, K., Jin, J., Vedadi, M., A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew. Chem. Int. Ed. Engl. 54 (2015), 5166–5170, 10.1002/anie.201412154.
71. Kassambara, A., Klein, B., Moreaux, J., MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem. Biophys. Res. Commun. 379 (2009), 840–845, 10.1016/j.bbrc.2008.12.093.
72. Katoh, M., Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy. Epigenomics 8 (2016), 285–305, 10.2217/epi.15.89.
73. Keniry, A., Gearing, L.J., Jansz, N., Liu, J., Holik, A.Z., Hickey, P.F., Kinkel, S.A., Moore, D.L., Breslin, K., Chen, K., Liu, R., Phillips, C., Pakusch, M., Biben, C., Sheridan, J.M., Kile, B.T., Carmichael, C., Ritchie, M.E., Hilton, D.J., Blewitt, M.E., Setdb1-mediated H3K9 methylation is enriched on the inactive X and plays a role in its epigenetic silencing. Epigenetics Chromatin, 9, 2016, 16, 10.1186/s13072-016-0064-6.
74. Kim, H., Heo, K., Kim, J.H., Kim, K., Choi, J., An, W., Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J. Biol. Chem. 284 (2009), 19867–19877, 10.1074/jbc.M109.021485.
75. Kim, J.-H., Sharma, A., Dhar, S.S., Lee, S.-H., Gu, B., Chan, C.-H., Lin, H.-K., Lee, M.G., UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 74 (2014), 1705–1717, 10.1158/0008-5472.CAN-13-1896.
76. Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., Wang, W., Haswell, J.R., Walensky, L.D., Hahn, W.C., Orkin, S.H., Roberts, C.W.M., SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21 (2015), 1491–1496, 10.1038/nm.3968.
77. Kim, K.H., Roberts, C.W.M., Targeting EZH2 in cancer. Nat. Med. 22 (2016), 128–134, 10.1038/nm.4036.
78. Kirmizis, A., Santos-Rosa, H., Penkett, C.J., Singer, M.A., Vermeulen, M., Mann, M., Bähler, J., Green, R.D., Kouzarides, T., Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature 449 (2007), 928–932, 10.1038/nature06160.
79. Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G.A.B., Otte, A.P., Hayes, D.F., Sabel, M.S., Livant, D., Weiss, S.J., Rubin, M.A., Chinnaiyan, A.M., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A 100 (2003), 11606–11611, 10.1073/pnas.1933744100.
80. Knutson, S.K., Kawano, S., Minoshima, Y., Warholic, N.M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Waters, N.J., Smith, J.J., Porter-Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., Richon, V.M., Uenaka, T., Pollock, R.M., Kuntz, K.W., Yokoi, A., Keilhack, H., Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13 (2014), 842–854, 10.1158/1535-7163.MCT-13-0773.
81. Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Porter-Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., Richon, V.M., Pollock, R.M., Kuntz, K.W., Keilhack, H., Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. U.S.A 110 (2013), 7922–7927, 10.1073/pnas.1303800110.
82. Koh, C.M., Bezzi, M., Guccione, E., The where and the how of PRMT5. Curr. Mol. Biol. Rep. 1 (2015), 19–28, 10.1007/s40610-015-0003-5.
83. Koppens, M., Van Lohuizen, M., Context-dependent actions of polycomb repressors in cancer. Oncogene 35 (2016), 1341–1352, 10.1038/onc.2015.195.
84. Krause, C.D., Yang, Z.-H., Kim, Y.-S., Lee, J.-H., Cook, J.R., Pestka, S., Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol. Ther. 113 (2007), 50–87, 10.1016/j.pharmthera.2006.06.007.
85. Kudithipudi, S., Jeltsch, A., Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim. Biophys. Acta 1846 (2014), 366–379, 10.1016/j.bbcan.2014.08.002.
86. Kuo, A.J., Cheung, P., Chen, K., Zee, B.M., Kioi, M., Lauring, J., Xi, Y., Park, B.H., Shi, X., Garcia, B.A., Li, W., Gozani, O., NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44 (2011), 609–620, 10.1016/j.molcel.2011.08.042.
87. LaFave, L.M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M.D., Hricik, T., Konstantinoff, K., Micol, J.-B., Durham, B., Knutson, S.K., Campbell, J.E., Blum, G., Shi, X., Doud, E.H., Krivtsov, A.V., Chung, Y.R., Khodos, I., de Stanchina, E., Ouerfelli, O., Adusumilli, P.S., Thomas, P.M., Kelleher, N.L., Luo, M., Keilhack, H., Abdel-Wahab, O., Melnick, A., Armstrong, S.A., Levine, R.L., Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21 (2015), 1344–1349, 10.1038/nm.3947.
88. Laible, G., Wolf, A., Dorn, R., Reuter, G., Nislow, C., Lebersorger, A., Popkin, D., Pillus, L., Jenuwein, T., Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J. 16 (1997), 3219–3232, 10.1093/emboj/16.11.3219.
89. Le Romancer, M., Treilleux, I., Leconte, N., Robin-Lespinasse, Y., Sentis, S., Bouchekioua-Bouzaghou, K., Goddard, S., Gobert-Gosse, S., Corbo, L., Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol. Cell 31 (2008), 212–221, 10.1016/j.molcel.2008.05.025.
90. Li, K.-C., Hua, K.-T., Lin, Y.-S., Su, C.-Y., Ko, J.-Y., Hsiao, M., Kuo, M.-L., Tan, C.-T., Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma. Mol. Cancer, 13, 2014, 172, 10.1186/1476-4598-13-172.
91. Li, X., Gonzalez, M.E., Toy, K., Filzen, T., Merajver, S.D., Kleer, C.G., Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am. J. Pathol. 175 (2009), 1246–1254, 10.2353/ajpath.2009.090042.
92. Lim, E., Vaillant, F., Wu, D., Forrest, N.C., Pal, B., Hart, A.H., Asselin-Labat, M.-L., Gyorki, D.E., Ward, T., Partanen, A., Feleppa, F., Huschtscha, L.I., Thorne, H.J., ConFab, k, Fox, S.B., Yan, M., French, J.D., Brown, M.A., Smyth, G.K., Visvader, J.E., Lindeman, G.J., Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15 (2009), 907–913, 10.1038/nm.2000.
93. Liu, B., Zhang, X., Song, F., Liu, Q., Dai, H., Zheng, H., Cui, P., Zhang, L., Zhang, W., Chen, K., A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer. Oncotarget 7 (2016), 34277–34287, 10.18632/oncotarget.9099.
94. Liu, B., Zhang, X., Song, F., Zheng, H., Zhao, Y., Li, H., Zhang, L., Yang, M., Zhang, W., Chen, K., MiR-502/SET8 regulatory circuit in pathobiology of breast cancer. Cancer Lett. 376 (2016), 259–267, 10.1016/j.canlet.2016.04.008.
95. Liu, L., Kimball, S., Liu, H., Holowatyj, A., Yang, Z.-Q., Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 6 (2015), 2466–2482, 10.18632/oncotarget.2967.
96. Liu, S., Brind'Amour, J., Karimi, M.M., Shirane, K., Bogutz, A., Lefebvre, L., Sasaki, H., Shinkai, Y., Lorincz, M.C., Setdb1 is required for germline development and silencing of H3K9me3-marked endogenous retroviruses in primordial germ cells. Genes Dev. 28 (2014), 2041–2055, 10.1101/gad.244848.114.
97. Magnani, L., Brunelle, M., Gévry, N., Lupien, M., Chromatin landscape and endocrine response in breast cancer. Epigenomics 4 (2012), 675–683, 10.2217/epi.12.64.
98. Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, B.D., Reinberg, D., Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32 (2008), 503–518, 10.1016/j.molcel.2008.11.004.
99. Martin, C., Zhang, Y., The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6 (2005), 838–849, 10.1038/nrm1761.
100. Mathioudaki, K., Scorilas, A., Ardavanis, A., Lymberi, P., Tsiambas, E., Devetzi, M., Apostolaki, A., Talieri, M., Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol. 32 (2011), 575–582, 10.1007/s13277-010-0153-2.
101. Matkar, S., Sharma, P., Gao, S., Gurung, B., Katona, B.W., Liao, J., Muhammad, A.B., Kong, X.-C., Wang, L., Jin, G., Dang, C.V., Hua, X., An epigenetic pathway regulates sensitivity of breast cancer cells to HER2 inhibition via FOXO/c-Myc axis. Cancer Cell 28 (2015), 472–485, 10.1016/j.ccell.2015.09.005.
102. Mazur, P.K., Reynoird, N., Khatri, P., Jansen, P.W.T.C., Wilkinson, A.W., Liu, S., Barbash, O., Van Aller, G.S., Huddleston, M., Dhanak, D., Tummino, P.J., Kruger, R.G., Garcia, B.A., Butte, A.J., Vermeulen, M., Sage, J., Gozani, O., SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510 (2014), 283–287, 10.1038/nature13320.
103. McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., Liu, Y., Graves, A.P., Pietra Della, A., Diaz, E., LaFrance, L.V., Mellinger, M., Duquenne, C., Tian, X., Kruger, R.G., McHugh, C.F., Brandt, M., Miller, W.H., Dhanak, D., Verma, S.K., Tummino, P.J., Creasy, C.L., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492 (2012), 108–112, 10.1038/nature11606.
104. Messaoudi, El, S., Fabbrizio, E., Rodriguez, C., Chuchana, P., Fauquier, L., Cheng, D., Theillet, C., Vandel, L., Bedford, M.T., Sardet, C., Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc. Natl. Acad. Sci. U.S.A 103 (2006), 13351–13356, 10.1073/pnas.0605692103.
105. Michalak, E.M., Nacerddine, K., Pietersen, A., Beuger, V., Pawlitzky, I., Cornelissen-Steijger, P., Wientjens, E., Tanger, E., Seibler, J., Van Lohuizen, M., Jonkers, J., Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool. Stem Cells 31 (2013), 1910–1920.
106. Mitchell, L.H., Boriack-Sjodin, P.A., Smith, S., Thomenius, M., Rioux, N., Munchhof, M., Mills, J.E., Klaus, C., Totman, J., Riera, T.V., Raimondi, A., Jacques, S.L., West, K., Foley, M., Waters, N.J., Kuntz, K.W., Wigle, T.J., Scott, M.P., Copeland, R.A., Smith, J.J., Chesworth, R., Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor. ACS Med. Chem. Lett. 7 (2016), 134–138, 10.1021/acsmedchemlett.5b00272.
107. Mitchell, L.H., Drew, A.E., Ribich, S.A., Rioux, N., Swinger, K.K., Jacques, S.L., Lingaraj, T., Boriack-Sjodin, P.A., Waters, N.J., Wigle, T.J., Moradei, O., Jin, L., Riera, T., Porter-Scott, M., Moyer, M.P., Smith, J.J., Chesworth, R., Copeland, R.A., Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 Tool compound. ACS Med. Chem. Lett. 6 (2015), 655–659, 10.1021/acsmedchemlett.5b00071.
108. Moelans, C.B., de Weger, R.A., Monsuur, H.N., Maes, A.H.J., van Diest, P.J., Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst) 33 (2010), 165–173, 10.3233/ACP-CLO-2010-0546.
109. Moelans, C.B., de Weger, R.A., Monsuur, H.N., Vijzelaar, R., van Diest, P.J., Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 23 (2010), 1029–1039, 10.1038/modpathol.2010.84.
110. Mounir, Z., Korn, J.M., Westerling, T., Lin, F., Kirby, C.A., Schirle, M., McAllister, G., Hoffman, G., Ramadan, N., Hartung, A., Feng, Y., Kipp, D.R., Quinn, C., Fodor, M., Baird, J., Schoumacher, M., Meyer, R., Deeds, J., Buchwalter, G., Stams, T., Keen, N., Sellers, W.R., Brown, M., Pagliarini, R.A., ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. Elife, 5, 2016, 10.7554/eLife.13964.
111. Mzoughi, S., Tan, Y.X., Low, D., Guccione, E., The role of PRDMs in cancer: one family, two sides. Curr. Opin. Genet. Dev. 36 (2016), 83–91, 10.1016/j.gde.2016.03.009.
112. Neault, M., Mallette, F.A., Vogel, G., Michaud-Levesque, J., Richard, S., Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor. Nucleic Acids Res. 40 (2012), 9513–9521, 10.1093/nar/gks764.
113. Nguyen, A.T., Zhang, Y., The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 25 (2011), 1345–1358, 10.1101/gad.2057811.
114. Nguyen, H., Allali-Hassani, A., Antonysamy, S., Chang, S., Chen, L.H., Curtis, C., Emtage, S., Fan, L., Gheyi, T., Li, F., Liu, S., Martin, J.R., Mendel, D., Olsen, J.B., Pelletier, L., Shatseva, T., Wu, S., Zhang, F.F., Arrowsmith, C.H., Brown, P.J., Campbell, R.M., Garcia, B.A., Barsyte-Lovejoy, D., Mader, M., Vedadi, M., LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2. J. Biol. Chem. 290 (2015), 13641–13653, 10.1074/jbc.M114.626861.
115. Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L.B., Martin, S., Wedge, D.C., Van Loo, P., Ju, Y.S., Smid, M., Brinkman, A.B., Morganella, S., Aure, M.R., Lingjærde, O.C., Langerød, A., Ringnér, M., Ahn, S.-M., Boyault, S., Brock, J.E., Broeks, A., Butler, A., Desmedt, C., Dirix, L., Dronov, S., Fatima, A., Foekens, J.A., Gerstung, M., Hooijer, G.K.J., Jang, S.J., Jones, D.R., Kim, H.-Y., King, T.A., Krishnamurthy, S., Lee, H.J., Lee, J.-Y., Li, Y., McLaren, S., Menzies, A., Mustonen, V., O'Meara, S., Pauporté, I., Pivot, X., Purdie, C.A., Raine, K., Ramakrishnan, K., Rodríguez-González, F.G., Romieu, G., Sieuwerts, A.M., Simpson, P.T., Shepherd, R., Stebbings, L., Stefansson, O.A., Teague, J., Tommasi, S., Treilleux, I., Van den Eynden, G.G., Vermeulen, P., Vincent-Salomon, A., Yates, L., Caldas, C., van't Veer, L., Tutt, A., Knappskog, S., Tan, B.K.T., Jonkers, J., Borg, Å., Ueno, N.T., Sotiriou, C., Viari, A., Futreal, P.A., Campbell, P.J., Span, P.N., Van Laere, S., Lakhani, S.R., Eyfjord, J.E., Thompson, A.M., Birney, E., Stunnenberg, H.G., van de Vijver, M.J., Martens, J.W.M., Børresen-Dale, A.-L., Richardson, A.L., Kong, G., Thomas, G., Stratton, M.R., Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534 (2016), 47–54, 10.1038/nature17676.
116. Nimura, K., Ura, K., Shiratori, H., Ikawa, M., Okabe, M., Schwartz, R.J., Kaneda, Y., A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–Hirschhorn syndrome. Nature 460 (2009), 287–291, 10.1038/nature08086.
117. Nishikawa, N., Toyota, M., Suzuki, H., Honma, T., Fujikane, T., Ohmura, T., Nishidate, T., Ohe-Toyota, M., Maruyama, R., Sonoda, T., Sasaki, Y., Urano, T., Imai, K., Hirata, K., Tokino, T., Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 67 (2007), 9649–9657, 10.1158/0008-5472.CAN-06-4111.
118. O'Carroll, D., Erhardt, S., Pagani, M., Barton, S.C., Surani, M.A., Jenuwein, T., The polycomb-group gene Ezh2 is required for early mouse development. Mol. Cell. Biol. 21 (2001), 4330–4336, 10.1128/MCB.21.13.4330-4336.2001.
119. O'Neill, D.J., Williamson, S.C., Alkharaif, D., Monteiro, I.C.M., Goudreault, M., Gaughan, L., Robson, C.N., Gingras, A.-C., Binda, O., SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells. Epigenetics 9 (2014), 942–950, 10.4161/epi.28864.
120. Oh, T.G., Bailey, P., Dray, E., Smith, A.G., Goode, J., Eriksson, N., Funder, J.W., Fuller, P.J., Simpson, E.R., Tilley, W.D., Leedman, P.J., Clarke, C.L., Grimmond, S., Dowhan, D.H., Muscat, G.E.O., PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Mol. Endocrinol. 28 (2014), 1166–1185, 10.1210/me.2013-1403.
121. Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V.M., Su, L., Xu, G., Zhang, Y., hDOT1L links histone methylation to leukemogenesis. Cell 121 (2005), 167–178, 10.1016/j.cell.2005.02.020.
122. Onder, T.T., Kara, N., Cherry, A., Sinha, A.U., Zhu, N., Bernt, K.M., Cahan, P., Marcarci, B.O., Unternaehrer, J., Gupta, P.B., Lander, E.S., Armstrong, S.A., Daley, G.Q., Chromatin-modifying enzymes as modulators of reprogramming. Nature 483 (2012), 598–602, 10.1038/nature10953.
123. Pal, B., Bouras, T., Shi, W., Vaillant, F., Sheridan, J.M., Fu, N., Breslin, K., Jiang, K., Ritchie, M.E., Young, M., Lindeman, G.J., Smyth, G.K., Visvader, J.E., Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep 3 (2013), 411–426, 10.1016/j.celrep.2012.12.020.
124. Pasqualucci, L., Compagno, M., Houldsworth, J., Monti, S., Grunn, A., Nandula, S.V., Aster, J.C., Murty, V.V., Shipp, M.A., Dalla-Favera, R., Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203 (2006), 311–317, 10.1084/jem.20052204.
125. Patani, N., Jiang, W.G., Newbold, R.F., Mokbel, K., Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res. 31 (2011), 4115–4125.
126. Patel, J.B., Appaiah, H.N., Burnett, R.M., Bhat-Nakshatri, P., Wang, G., Mehta, R., Badve, S., Thomson, M.J., Hammond, S., Steeg, P., Liu, Y., Nakshatri, H., Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 30 (2011), 1290–1301, 10.1038/onc.2010.510.
127. Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lønning, P.E., Børresen-Dale, A.L., Brown, P.O., Botstein, D., Molecular portraits of human breast tumours. Nature 406 (2000), 747–752, 10.1038/35021093.
128. Peserico, A., Germani, A., Sanese, P., Barbosa, A.J., di Virgilio, V., Fittipaldi, R., Fabini, E., Bertucci, C., Varchi, G., Moyer, M.P., Caretti, G., del Rio, A., Simone, C., A SMYD3 small-molecule inhibitor impairing cancer cell growth. J. Cell. Physiol. 230 (2015), 2447–2460, 10.1002/jcp.24975.
129. Peters, A.H., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., Opravil, S., Doyle, M., Sibilia, M., Jenuwein, T., Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107 (2001), 323–337.
130. Phalke, S., Mzoughi, S., Bezzi, M., Jennifer, N., Mok, W.C., Low, D.H.P., Thike, A.A., Kuznetsov, V.A., Tan, P.H., Voorhoeve, P.M., Guccione, E., p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6. Nucleic Acids Res. 40 (2012), 9534–9542, 10.1093/nar/gks858.
131. Polstein, L.R., Perez-Pinera, P., Kocak, D.D., Vockley, C.M., Bledsoe, P., Song, L., Safi, A., Crawford, G.E., Reddy, T.E., Gersbach, C.A., Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Res. 25 (2015), 1158–1169, 10.1101/gr.179044.114.
132. Powers, M.A., Fay, M.M., Factor, R.E., Welm, A.L., Ullman, K.S., Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 71 (2011), 5579–5587, 10.1158/0008-5472.CAN-11-0458.
133. Puppe, J., Drost, R., Liu, X., Joosse, S.A., Evers, B., Cornelissen-Steijger, P., Nederlof, P., Yu, Q., Jonkers, J., van Lohuizen, M., Pietersen, A.M., BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res., 11, 2009, R63, 10.1186/bcr2354.
134. Raaphorst, F.M., Meijer, C.J.L.M., Fieret, E., Blokzijl, T., Mommers, E., Buerger, H., Packeisen, J., Sewalt, R.A.B., Otte, A.P., van Diest, P.J., Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5 (2003), 481–488.
135. Rao, B., Shibata, Y., Strahl, B.D., Lieb, J.D., Dimethylation of histone H3 at lysine 36 demarcates regulatory and nonregulatory chromatin genome-wide. Mol. Cell. Biol. 25 (2005), 9447–9459, 10.1128/MCB.25.21.9447-9459.2005.
136. Rao, R.C., Dou, Y., Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer 15 (2015), 334–346, 10.1038/nrc3929.
137. Rathert, P., Dhayalan, A., Murakami, M., Zhang, X., Tamas, R., Jurkowska, R., Komatsu, Y., Shinkai, Y., Cheng, X., Jeltsch, A., Protein lysine methyltransferase G9a acts on non-histone targets. Nat. Chem. Biol. 4 (2008), 344–346, 10.1038/nchembio.88.
138. Rayasam, G.V., Wendling, O., Angrand, P.-O., Mark, M., Niederreither, K., Song, L., Lerouge, T., Hager, G.L., Chambon, P., Losson, R., NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J. 22 (2003), 3153–3163, 10.1093/emboj/cdg288.
139. Reijm, E.A., Jansen, M.P.H.M., Ruigrok-Ritstier, K., van Staveren, I.L., Look, M.P., van Gelder, M.E.M., Sieuwerts, A.M., Sleijfer, S., Foekens, J.A., Berns, E.M.J.J., Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res. Treat. 125 (2011), 387–394, 10.1007/s10549-010-0836-9.
140. Ross, J.S., Badve, S., Wang, K., Sheehan, C.E., Boguniewicz, A.B., Otto, G.A., Yelensky, R., Lipson, D., Ali, S., Morosini, D., Chliemlecki, J., Elvin, J.A., Miller, V.A., Stephens, P.J., Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Arch. Pathol. Lab. Med. 139 (2015), 642–649, 10.5858/arpa.2014-0200-OA.
141. Saddic, L.A., West, L.E., Aslanian, A., Yates, J.R., Rubin, S.M., Gozani, O., Sage, J., Methylation of the retinoblastoma tumor suppressor by SMYD2. J. Biol. Chem. 285 (2010), 37733–37740, 10.1074/jbc.M110.137612.
142. Salz, T., Deng, C., Pampo, C., Siemann, D., Qiu, Y., Brown, K., Huang, S., Histone methyltransferase hSETD1A is a novel regulator of metastasis in breast cancer. Mol. Cancer Res. 13 (2015), 461–469, 10.1158/1541-7786.MCR-14-0389.
143. Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., Reinberg, D., Jenuwein, T., A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18 (2004), 1251–1262, 10.1101/gad.300704.
144. Schoumacher, M., Le Corre, S., Houy, A., Mulugeta, E., Stern, M.-H., Roman-Roman, S., Margueron, R., Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status. Nat. Med. 22 (2016), 577–578, 10.1038/nm.4098.
145. Schwarz, D., Varum, S., Zemke, M., Schöler, A., Baggiolini, A., Draganova, K., Koseki, H., Schübeler, D., Sommer, L., Ezh2 is required for neural crest-derived cartilage and bone formation. Development 141 (2014), 867–877, 10.1242/dev.094342.
146. Seligson, D.B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., Kurdistani, S.K., Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005), 1262–1266, 10.1038/nature03672.
147. Shema, E., Jones, D., Shoresh, N., Donohue, L., Ram, O., Bernstein, B.E., Single-molecule decoding of combinatorially modified nucleosomes. Science 352 (2016), 717–721, 10.1126/science.aad7701.
148. Shen, X., Liu, Y., Hsu, Y.-J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.-C., Orkin, S.H., EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32 (2008), 491–502, 10.1016/j.molcel.2008.10.016.
149. Shinkai, Y., Tachibana, M., H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev. 25 (2011), 781–788, 10.1101/gad.2027411.
150. Si, W., Huang, W., Zheng, Y., Yang, Y., Liu, X., Shan, L., Zhou, X., Wang, Y., Su, D., Gao, J., Yan, R., Han, X., Li, W., He, L., Shi, L., Xuan, C., Liang, J., Sun, L., Wang, Y., Shang, Y., Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell 27 (2015), 822–836, 10.1016/j.ccell.2015.04.011.
151. Song, X., Gao, T., Wang, N., Feng, Q., You, X., Ye, T., Lei, Q., Zhu, Y., Xiong, M., Xia, Y., Yang, F., Shi, Y., Wei, Y., Zhang, L., Yu, L., Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci. Rep., 6, 2016, 20864, 10.1038/srep20864.
152. Souroullas, G.P., Jeck, W.R., Parker, J.S., Simon, J.M., Liu, J.-Y., Paulk, J., Xiong, J., Clark, K.S., Fedoriw, Y., Qi, J., Burd, C.E., Bradner, J.E., Sharpless, N.E., An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat. Med. 22 (2016), 632–640, 10.1038/nm.4092.
153. Squazzo, S.L., O'Geen, H., Komashko, V.M., Krig, S.R., Jin, V.X., Jang, S.-W., Margueron, R., Reinberg, D., Green, R., Farnham, P.J., Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 16 (2006), 890–900, 10.1101/gr.5306606.
154. Stein, C., Riedl, S., Rüthnick, D., Nötzold, R.R., Bauer, U.-M., The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes. Nucleic Acids Res. 40 (2012), 9522–9533, 10.1093/nar/gks767.
155. Stojic, L., Jasencakova, Z., Prezioso, C., Stützer, A., Bodega, B., Pasini, D., Klingberg, R., Mozzetta, C., Margueron, R., Puri, P.L., Schwarzer, D., Helin, K., Fischle, W., Orlando, V., Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. Epigenetics Chromatin, 4, 2011, 16, 10.1186/1756-8935-4-16.
156. Stolzenburg, S., Beltran, A.S., Swift-Scanlan, T., Rivenbark, A.G., Rashwan, R., Blancafort, P., Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene 34 (2015), 5427–5435, 10.1038/onc.2014.470.
157. Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, H., Matese, J.C., Brown, P.O., Botstein, D., Lønning, P.E., Børresen-Dale, A.L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A 98 (2001), 10869–10874, 10.1073/pnas.191367098.
158. Tachibana, M., Sugimoto, K., Nozaki, M., Ueda, J., Ohta, T., Ohki, M., Fukuda, M., Takeda, N., Niida, H., Kato, H., Shinkai, Y., G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16 (2002), 1779–1791, 10.1101/gad.989402.
159. Tan, J., Ong, C.K., Lim, W.K., Ng, C.C.Y., Thike, A.A., Ng, L.M., Rajasegaran, V., Myint, S.S., Nagarajan, S., Thangaraju, S., Dey, S., Nasir, N.D.M., Wijaya, G.C., Lim, J.Q., Huang, D., Li, Z., Wong, B.H., Chan, J.Y.S., McPherson, J.R., Cutcutache, I., Poore, G., Tay, S.T., Tan, W.J., Putti, T.C., Ahmad, B.S., Iau, P., Chan, C.W., Tang, A.P.H., Yong, W.S., Madhukumar, P., Ho, G.H., Tan, V.K.M., Wong, C.Y., Hartman, M., Ong, K.W., Tan, B.K.T., Rozen, S.G., Tan, P., Tan, P.H., Teh, B.T., Genomic landscapes of breast fibroepithelial tumors. Nat. Genet. 47 (2015), 1341–1345, 10.1038/ng.3409.
160. Tee, W.-W., Pardo, M., Theunissen, T.W., Yu, L., Choudhary, J.S., Hajkova, P., Surani, M.A., Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 24 (2010), 2772–2777, 10.1101/gad.606110.
161. Teyssier, C., Le Romancer, M., Sentis, S., Jalaguier, S., Corbo, L., Cavaillès, V., Protein arginine methylation in estrogen signaling and estrogen-related cancers. Trends Endocrinol. Metab. 21 (2010), 181–189, 10.1016/j.tem.2009.11.002.
162. Thakore, P.I., Black, J.B., Hilton, I.B., Gersbach, C.A., Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat. Methods 13 (2016), 127–137, 10.1038/nmeth.3733.
163. Thakore, P.I., D'Ippolito, A.M., Song, L., Safi, A., Shivakumar, N.K., Kabadi, A.M., Reddy, T.E., Crawford, G.E., Gersbach, C.A., Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 12 (2015), 1143–1149, 10.1038/nmeth.3630.
164. Thomassen, M., Tan, Q., Kruse, T.A., Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res. Treat. 113 (2009), 239–249, 10.1007/s10549-008-9927-2.
165. Vakoc, C.R., Sachdeva, M.M., Wang, H., Blobel, G.A., Profile of histone lysine methylation across transcribed mammalian chromatin. Mol. Cell. Biol. 26 (2006), 9185–9195, 10.1128/MCB.01529-06.
166. van 't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R., Friend, S.H., Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002), 530–536, 10.1038/415530a.
167. Van Aller, G.S., Graves, A.P., Elkins, P.A., Bonnette, W.G., McDevitt, P.J., Zappacosta, F., Annan, R.S., Dean, T.W., Su, D.-S., Carpenter, C.L., Mohammad, H.P., Kruger, R.G., Structure-based design of a novel SMYD3 inhibitor that bridges the SAM-and MEKK2-binding pockets. Structure 24 (2016), 774–781, 10.1016/j.str.2016.03.010.
168. Vedadi, M., Barsyte-Lovejoy, D., Liu, F., Rival-Gervier, S., Allali-Hassani, A., Labrie, V., Wigle, T.J., Dimaggio, P.A., Wasney, G.A., Siarheyeva, A., Dong, A., Tempel, W., Wang, S.-C., Chen, X., Chau, I., Mangano, T.J., Huang, X.-P., Simpson, C.D., Pattenden, S.G., Norris, J.L., Kireev, D.B., Tripathy, A., Edwards, A., Roth, B.L., Janzen, W.P., Garcia, B.A., Petronis, A., Ellis, J., Brown, P.J., Frye, S.V., Arrowsmith, C.H., Jin, J., A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7 (2011), 566–574, 10.1038/nchembio.599.
169. Vougiouklakis, T., Hamamoto, R., Nakamura, Y., Saloura, V., The NSD family of protein methyltransferases in human cancer. Epigenomics 7 (2015), 863–874, 10.2217/epi.15.32.
170. Wagner, E.J., Carpenter, P.B., Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 13 (2012), 115–126, 10.1038/nrm3274.
171. Wang, C., Guo, Z., Wu, C., Li, Y., Kang, S., A polymorphism at the miR-502 binding site in the 3′ untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer. Cancer Genet. 205 (2012), 373–376, 10.1016/j.cancergen.2012.04.010.
172. Wang, F., Qi, L.S., Applications of CRISPR genome engineering in cell biology. Trends Cell Biol, 2016, 10.1016/j.tcb.2016.08.004 in press.
173. Wang, J., Duan, Z., Nugent, Z., Zou, J.X., Borowsky, A.D., Zhang, Y., Tepper, C.G., Li, J.J., Fiehn, O., Xu, J., Kung, H.-J., Murphy, L.C., Chen, H.-W., Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 378 (2016), 69–79, 10.1016/j.canlet.2016.05.004.
174. Wang, L., Jin, Q., Lee, J.-E., Su, I.-H., Ge, K., Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 7317–7322, 10.1073/pnas.1000031107.
175. Wang, X., Belguise, K., O'Neill, C.F., Sánchez-Morgan, N., Romagnoli, M., Eddy, S.F., Mineva, N.D., Yu, Z., Min, C., Trinkaus-Randall, V., Chalbos, D., Sonenshein, G.E., RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol. Cell. Biol. 29 (2009), 3832–3844, 10.1128/MCB.00032-09.
176. Wei, H., Mundade, R., Lange, K.C., Lu, T., Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle 13 (2014), 32–41, 10.4161/cc.27353.
177. Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, N.V., Albarracin, C., Yu, D., Abbruzzese, J.L., Mills, G.B., Bast, R.C., Hortobagyi, G.N., Hung, M.-C., Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47 (2008), 701–706, 10.1002/mc.20413.
178. Wozniak, R.J., Klimecki, W.T., Lau, S.S., Feinstein, Y., Futscher, B.W., 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26 (2007), 77–90, 10.1038/sj.onc.1209763.
179. Wray, J., Williamson, E.A., Royce, M., Shaheen, M., Beck, B.D., Lee, S.-H., Nickoloff, J.A., Hromas, R., Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS One, 4, 2009, e5323, 10.1371/journal.pone.0005323.
180. Xu, J., Shao, Z., Li, D., Xie, H., Kim, W., Huang, J., Taylor, J.E., Pinello, L., Glass, K., Jaffe, J.D., Yuan, G.-C., Orkin, S.H., Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. Mol. Cell 57 (2015), 304–316, 10.1016/j.molcel.2014.12.009.
181. Yang, S., Zhang, Y., Meng, F., Liu, Y., Xia, B., Xiao, M., Xu, Y., Ning, X., Li, H., Lou, G., Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma. Biomarkers 18 (2013), 257–263, 10.3109/1354750X.2013.773082.
182. Yang, Y., Bedford, M.T., Protein arginine methyltransferases and cancer. Nat. Rev. Cancer 13 (2013), 37–50, 10.1038/nrc3409.
183. Yang, Z.-Q., Liu, G., Bollig-Fischer, A., Giroux, C.N., Ethier, S.P., Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 70 (2010), 8487–8497, 10.1158/0008-5472.CAN-10-1013.
184. Yao, R., Jiang, H., Ma, Y., Wang, L., Wang, L., Du, J., Hou, P., Gao, Y., Zhao, L., Wang, G., Zhang, Y., Liu, D.-X., Huang, B., Lu, J., PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer. Cancer Res. 74 (2014), 5656–5667, 10.1158/0008-5472.CAN-14-0800.
185. Ye, K., Wang, J., Jayasinghe, R., Lameijer, E.-W., McMichael, J.F., Ning, J., McLellan, M.D., Xie, M., Cao, S., Yellapantula, V., Huang, K.-L., Scott, A., Foltz, S., Niu, B., Johnson, K.J., Moed, M., Slagboom, P.E., Chen, F., Wendl, M.C., Ding, L., Systematic discovery of complex insertions and deletions in human cancers. Nat. Med. 22 (2016), 97–104, 10.1038/nm.4002.
186. Yokoyama, Y., Matsumoto, A., Hieda, M., Shinchi, Y., Ogihara, E., Hamada, M., Nishioka, Y., Kimura, H., Yoshidome, K., Tsujimoto, M., Matsuura, N., Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res., 16, 2014, R66, 10.1186/bcr3681.
187. Yoon, K.-A., Gil, H.J., Han, J., Park, J., Lee, J.S., Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J. Thorac. Oncol. 5 (2010), 10–16, 10.1097/JTO.0b013e3181c422d9.
188. Yu, J., Angelin-Duclos, C., Greenwood, J., Liao, J., Calame, K., Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol. Cell. Biol. 20 (2000), 2592–2603.
189. Yu, Z., Chen, T., Hébert, J., Li, E., Richard, S., A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. Mol. Cell. Biol. 29 (2009), 2982–2996, 10.1128/MCB.00042-09.
190. Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, M.S., Zhsng, C.-Z., Wala, J., Mermel, C.H., Sougnez, C., Gabriel, S.B., Hernandez, B., Shen, H., Laird, P.W., Getz, G., Meyerson, M., Beroukhim, R., Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45 (2013), 1134–1140, 10.1038/ng.2760.
191. Zalatan, J.G., Lee, M.E., Almeida, R., Gilbert, L.A., Whitehead, E.H., La Russa, M., Tsai, J.C., Weissman, J.S., Dueber, J.E., Qi, L.S., Lim, W.A., Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160 (2015), 339–350, 10.1016/j.cell.2014.11.052.
192. Zhang, L., Deng, L., Chen, F., Yao, Y., Wu, B., Wei, L., Mo, Q., Song, Y., Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 5 (2014), 10665–10677, 10.18632/oncotarget.2496.
193. Zhang, T., Cooper, S., Brockdorff, N., The interplay of histone modifications – writers that read. EMBO Rep. 16 (2015), 1467–1481, 10.15252/embr.201540945.
194. Zhang, X., Peng, D., Xi, Y., Yuan, C., Sagum, C.A., Klein, B.J., Tanaka, K., Wen, H., Kutateladze, T.G., Li, W., Bedford, M.T., Shi, X., G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression. Nat. Commun., 7, 2016, 10810, 10.1038/ncomms10810.
195. Zhang, X., Tanaka, K., Yan, J., Li, J., Peng, D., Jiang, Y., Yang, Z., Barton, M.C., Wen, H., Shi, X., Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation. Proc. Natl. Acad. Sci. U.S.A 110 (2013), 17284–17289, 10.1073/pnas.1307959110.
196. Zhao, Q., Rank, G., Tan, Y.T., Li, H., Moritz, R.L., Simpson, R.J., Cerruti, L., Curtis, D.J., Patel, D.J., Allis, C.D., Cunningham, J.M., Jane, S.M., PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 16 (2009), 304–311, 10.1038/nsmb.1568.
197. Zhong, J., Cao, R.-X., Liu, J.-H., Liu, Y.-B., Wang, J., Liu, L.-P., Chen, Y.-J., Yang, J., Zhang, Q.-H., Wu, Y., Ding, W.-J., Hong, T., Xiao, X.-H., Zu, X.-Y., Wen, G.-B., Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein. Oncogene 33 (2014), 5546–5558, 10.1038/onc.2013.500.
198. Zhong, J., Cao, R.-X., Zu, X.-Y., Hong, T., Yang, J., Liu, L., Xiao, X.-H., Ding, W.-J., Zhao, Q., Liu, J.-H., Wen, G.-B., Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. FEBS J. 279 (2012), 316–335, 10.1111/j.1742-4658.2011.08426.x.
199. Zingg, D., Debbache, J., Schaefer, S.M., Tuncer, E., Frommel, S.C., Cheng, P., Arenas-Ramirez, N., Haeusel, J., Zhang, Y., Bonalli, M., McCabe, M.T., Creasy, C.L., Levesque, M.P., Boyman, O., Santoro, R., Shakhova, O., Dummer, R., Sommer, L., The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun., 6, 2015, 6051, 10.1038/ncomms7051.